News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GATC Biotech Offers World's Fastest Exome Sequencing Service: 1-Week Exome Diagnostic


6/5/2013 10:43:10 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Konstanz, Germany, June 5, 2013 / B3C newswire / – GATC Biotech, the European leader for DNA sequencing, has designed InView™ 1-Week Exome Diagnostic especially for diagnostic purposes. This service enables early detection of multiple genetic variants presumably responsible for diverse genetic disease markers within just 7 days, the world’s fastest turn-around time available. With its DIN EN ISO/IEC 17025 certified Next Gen Sequencing laboratories, GATC Biotech offers this application e.g. for detection of cancerous cells or early detection of other genetic diseases.

The application supports clinicians to initiate urgent treatments and opens the way to a more personalised patient care in the field of cancer, metabolic dysfunctions and immunological diseases. With a combination of standardised workflows and highest quality standards, InView™ 1-Week Exome Diagnostic is an overall solution for fast and reliable variant detection. Focusing on the functional relevant coding regions, only approx. 1% of the human genome (the exome) needs to be sequenced. This provides an efficient advantage for diagnostics and clinical research.

“Next Generation Sequencing technologies have set a new level in the field of clinical research and diagnostics. 1-Week Exome Diagnostic is an all-in-one service delivering rapid results for early detection of diseases for our customers in diagnostics, clinical and pharmaceutical research”, tells Dr. Marcus Benz, COO at GATC Biotech. “Being the leading service provider for NGS solutions, scientists can profit from our thorough experience in exome analysis while receiving accurate results in only 7 days.”

Essential requirements for the competence of analysis and calibration laboratories such as DIN EN ISO/IEC 17025 and DIN EN ISO 9001 by the national accreditation body for the Federal Republic of Germany (DAkkS) have been fulfilled by GATC Biotech’s NGS laboratories. The application is based on Agilent SureSelectXT Human All Exon V5 enrichment and Illumina MiSeq.

About GATC Biotech

GATC Biotech is Europe’s leading service provider of DNA sequencing with more than 10,000 academic and industrial customers worldwide. For over two decades, we have offered sequencing and bioinformatics solutions from single samples up to large scale projects. GATC Biotech has sequenced more than 5 million samples, ten thousands of bacterial, plant and other whole genomes as well as hundreds of whole human genomes.

Having Agilent and Illumina Certified Service Provider status, GATC Biotech offers true multiplatform sequencing using all leading sequencing technologies in its own labs. In order to evaluate these immense data quantities professionally, GATC Biotech keeps its own IT farm.

Headquartered in Constance Germany, the company houses its ISO 17025 certified Genome and Diagnostic Centre with a focus on Next and Third Generation sequencing. The European Custom Sequencing Centre located in Cologne focuses on Sanger Sequencing and serves as the logistical hub within Europe. All laboratories have highly integrated and fully automatic processing pipelines and enable full compliance with latest state-of-the-art quality standards. Since 2010, GATC Biotech has been a key supplier for the International Cancer Genome Project.

GATC Biotech´s subsidiary LifeCodexx emphasizes the development of clinically validated molecular diagnostic tests and offers a risk-free alternative to common invasive examination methods such as amniocentesis.

Contact

Lisa-Annina Quintes

GATC Biotech AG

Jakob-Stadler-Platz 7

78467 Konstanz

Germany

Phone: +49 (0) 7531-81604117

Fax: +49 (0) 7531-816081

l.quintes@gatc-biotech.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES